Gilead Sciences offers innovative drugs and boasts a 45,000% return since IPO, highlighting substantial growth. Investing in Gilead is accessible via brokerage accounts, using simple steps to buy ...

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7. Analysts expect the health care company to report quarterly ...

The market expects Gilead Sciences (GILD) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook ...

Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On ...

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth ...

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc.

Gilead Sciences ( GILD) has agreed to acquire biotechnology company Arcellx ( ACLX) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an ...